BUD vs NEO
BUD (BUD) versus NeoGenomics Inc (NEO) — a side-by-side from cached financials, not a winner call.
BUD (BUD) common stock.
NeoGenomics Inc (NEO) is a diagnostics & research company listed on US.
BUD does not have a complete income-statement cache yet.
Latest reported NEO revenue for 2026-06-30 was $388.3M. Net income was -$14.9M. NEO currently screens at market cap $924.0M.
BUD currently screens at market cap $0. NEO currently screens at market cap $924.0M.
Not investment advice. Open the BUD and NEO stock pages for the full models.
Not investment advice.